|
|
 |
|
Viewing report
|
|
|
|
Global Cancer Treatment Forecast to 2012
RNCOS E-Services Private Limited, Aug 2008, Pages: 85
High number of unmet needs and an ever-increasing prevalence of cancer has created a gold rush among drug companies to enter the cancer market. Here, launching a drug successfully is risky, however, if launched, commercial gains completely surpass the expenditures incurred, says 'Global Cancer Treatment Forecast to 2012”, the new research report from RNCOS.
Cancer represents the fastest growing therapy segment in the pharmaceutical market. This segment has become the centre of focus for drug firms and investors, and has garnered more attention than any other therapy segment; nearly every mid-size and large pharmaceutical/biotech company today is linked to a cancer pipeline.
Drugs available in the market today do give some respite to patients but fail to address a number of complications. So manufacturers are working to solve the problem and in future, we may see a number of drug launches which will significantly reduce the complications and increase life expectancy significantly.
This report is a comprehensive study on the global cancer market and gives statistics and analysis on cancer prevalence, market size, market structure, key drug segments, market share of key players and drugs, major opportunity areas and trends in technology development. Both the past and current market trends have been covered in the report along the factors that are expected to impact the market in future. This report provides answers to a number of questions vital for firms looking for making an investment into the sector.
Key Findings
-From more than 12 Million newly diagnosed cancer cases in 2007, the number of newly diagnosed global cancer cases is expected to reach over 17 Million by 2020.
-Growing at a CAGR of 12.3% between 2007 and 2012, the global market for cancer drugs is expected to cross US$ 78 Billion by 2012.
-Cancer vaccines and antiangiogenics will record the fastest growth rate between 2007 and 2012.
-Drug manufactures are now focused on developing target therapies. These drugs attack target cells and thus limit the severity of side effects.
-The US is the largest market for cancer drugs, followed by Europe and Japan.
-Drugs for cancer represent the largest therapy area under clinical development; however, when it comes to approval rates, drugs for cancer have the worst approval rates.
Key Issues Analyzed
-Evaluation of past, current and future market trends.
-Discussion on major cancer drugs and their markets.
-Future forecast of the cancer market.
-Analysis of various challenges and opportunities for the industry.
-Categories of players operating in the market and their present and future revenue forecast.
-Analysis of key Geographical markets
Research Methodology Used
Information Sources
The information given in the report has been sourced from various credible sources like books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to over 3000 paid databases.
Analysis Methods
The analysis methods used in the report include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.
Customers who bought this item also bought
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Global Prostate Cancer Therapeutics Market (2010 – 2020) (Opportunity Analysis, Pipeline Assessment & Market Forecast)
Pancreatic Cancer Drugs - Global Strategic Business Report
Personalized Medicine - Scientific and Commercial Aspects
Prostate Cancer Therapeutics - A Global Market Perspective
VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011
Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries.
Liver Cancer Drugs - Global Strategic Business Report
|
|
|
|
